Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00256711




Registration number
NCT00256711
Ethics application status
Date submitted
20/11/2005
Date registered
22/11/2005
Date last updated
23/04/2009

Titles & IDs
Public title
Phase II Iressa Versus Vinorelbine (INVITE)
Scientific title
A Randomised, Open Label, Parallel Group, Multi-Centre, Phase II Study of Progression Free Survival Comparing ZD1839 (IRESSA™) (250 MG Tablet) Versus Vinorelbine (30 MG/M2 Infusion) in Chemonaive, Elderly Patients With Locally Advanced (Stage IIIB) or Metastatic (Stage IV) NSCLC
Secondary ID [1] 0 0
INVITE
Secondary ID [2] 0 0
D791AC00001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non-Small-Cell Lung Carcinoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Non small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
To compare ZD1839 and vinorelbine in terms of progression free survival
Timepoint [1] 0 0
Secondary outcome [1] 0 0
To compare ZD1839 and vinorelbine in terms of pulmonary symptom improvement weekly for 18 weeks.
Timepoint [1] 0 0
Secondary outcome [2] 0 0
To compare ZD1839 and vinorelbine in terms of quality of life 3 weekly for 18 weeks then 6 weekly.
Timepoint [2] 0 0
Secondary outcome [3] 0 0
To compare ZD1839 and vinorelbine in terms of adverse event profile continuous monitoring.
Timepoint [3] 0 0
Secondary outcome [4] 0 0
To compare ZD1839 and vinorelbine in terms of overall objective tumour response rate (complete response and partial response) 6 weekly to progression.
Timepoint [4] 0 0
Secondary outcome [5] 0 0
To compare ZD1839 and vinorelbine in terms of overall survival (time to death) continuous monitoring
Timepoint [5] 0 0

Eligibility
Key inclusion criteria
* Histologically confirmed NSCLC and willing to provide paraffin embedded tumour tissue
* NSCLC - locally advanced (Stage IIIB) or metastatic (stage IV) disease, not amenable to curative surgery or radiotherapy chemonaïve, life expectancy of 12 weeks
* WHO Performance status <= 2
Minimum age
70 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Newly diagnosed CNS metastases
* Less than 4 weeks since completion of radiotherapy or persistence of any radiotherapy related toxicity.
* Hypersensitivity to ZD1839 or intravenous vinorelbine
* Prior treatment with EGFR inhibitors
* Other co-existing malignancies
* ALT/AST >2.5 x ULRR
* ANC < 2.0 x 10^9/L or platelets < 100 x 10^9/L

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/07/2004
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/02/2006
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,WA
Recruitment hospital [1] 0 0
Research Site - St. Leonards
Recruitment hospital [2] 0 0
Research Site - Westmead
Recruitment hospital [3] 0 0
Research Site - South Brisbane
Recruitment hospital [4] 0 0
Research Site - Nedlands
Recruitment hospital [5] 0 0
Research Site - Victoria
Recruitment postcode(s) [1] 0 0
- St. Leonards
Recruitment postcode(s) [2] 0 0
- Westmead
Recruitment postcode(s) [3] 0 0
- South Brisbane
Recruitment postcode(s) [4] 0 0
- Nedlands
Recruitment postcode(s) [5] 0 0
- Victoria
Recruitment outside Australia
Country [1] 0 0
Brazil
State/province [1] 0 0
CE
Country [2] 0 0
Brazil
State/province [2] 0 0
GO
Country [3] 0 0
Brazil
State/province [3] 0 0
RJ
Country [4] 0 0
Brazil
State/province [4] 0 0
SP
Country [5] 0 0
Czech Republic
State/province [5] 0 0
CZ
Country [6] 0 0
Czech Republic
State/province [6] 0 0
Hradec Kralove
Country [7] 0 0
Czech Republic
State/province [7] 0 0
Kutná Hora
Country [8] 0 0
Czech Republic
State/province [8] 0 0
Olomouc
Country [9] 0 0
Czech Republic
State/province [9] 0 0
Ostrava - Poruba
Country [10] 0 0
Czech Republic
State/province [10] 0 0
Ostrava
Country [11] 0 0
Czech Republic
State/province [11] 0 0
Plzen
Country [12] 0 0
France
State/province [12] 0 0
Marseille Cedex 09
Country [13] 0 0
France
State/province [13] 0 0
Montpellier Cedex 5
Country [14] 0 0
France
State/province [14] 0 0
Montpellier Cedex
Country [15] 0 0
France
State/province [15] 0 0
Pierre Benite Cedex
Country [16] 0 0
France
State/province [16] 0 0
Vesoul Cedex
Country [17] 0 0
Germany
State/province [17] 0 0
Baden-Württemberg
Country [18] 0 0
Germany
State/province [18] 0 0
Bayern
Country [19] 0 0
Germany
State/province [19] 0 0
Sachsen-Anhalt
Country [20] 0 0
Germany
State/province [20] 0 0
Schleswig-Holstein
Country [21] 0 0
Germany
State/province [21] 0 0
Berlin
Country [22] 0 0
Germany
State/province [22] 0 0
Großhansdorf
Country [23] 0 0
Germany
State/province [23] 0 0
Halle
Country [24] 0 0
Germany
State/province [24] 0 0
Hamburg
Country [25] 0 0
Germany
State/province [25] 0 0
Mainz
Country [26] 0 0
Italy
State/province [26] 0 0
Ancona
Country [27] 0 0
Italy
State/province [27] 0 0
BG
Country [28] 0 0
Italy
State/province [28] 0 0
BO
Country [29] 0 0
Italy
State/province [29] 0 0
CT
Country [30] 0 0
Italy
State/province [30] 0 0
MI
Country [31] 0 0
Italy
State/province [31] 0 0
MO
Country [32] 0 0
Italy
State/province [32] 0 0
PR
Country [33] 0 0
Italy
State/province [33] 0 0
TO
Country [34] 0 0
Italy
State/province [34] 0 0
Napoli
Country [35] 0 0
Korea, Republic of
State/province [35] 0 0
Seoul
Country [36] 0 0
South Africa
State/province [36] 0 0
Cape Town
Country [37] 0 0
South Africa
State/province [37] 0 0
Durban
Country [38] 0 0
Taiwan
State/province [38] 0 0
Taichung
Country [39] 0 0
Taiwan
State/province [39] 0 0
Taipei
Country [40] 0 0
United Kingdom
State/province [40] 0 0
Cambrideshire
Country [41] 0 0
United Kingdom
State/province [41] 0 0
West Midlands
Country [42] 0 0
United Kingdom
State/province [42] 0 0
Aberdeen
Country [43] 0 0
United Kingdom
State/province [43] 0 0
Dundee
Country [44] 0 0
United Kingdom
State/province [44] 0 0
Glasgow
Country [45] 0 0
United Kingdom
State/province [45] 0 0
Nottingham
Country [46] 0 0
United Kingdom
State/province [46] 0 0
Sheffield

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AstraZeneca
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
AstraZeneca Iressa Medical Science Director, MD
Address 0 0
AstraZeneca
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT00256711